Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
Holding VNRX?
Track your performance easily
VNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.43 - $1.23
Previous CloseN/A
Volume29.92K
Average Volume (3M)398.66K
Market Cap
$61.61M
Enterprise Value$52.16M
Total Cash (Recent Filing)$21.68M
Total Debt (Recent Filing)$1.32M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Mar 12, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding95,967,850
10 Day Avg. Volume92,203
30 Day Avg. Volume398,663
Standard Deviation0.17
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)46.27
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue43.21
Enterprise Value/Gross Profit67.27
Enterprise Value/Ebitda-1.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
VolitionRX News
PremiumCompany Announcements
VolitionRx Posts Strong Q3 Growth and Strategic Advances
PremiumPre-Earnings
Is VNRX a Buy, Before Earnings?PremiumCompany Announcements
VolitionRX Confirms Dr. Michel’s Leadership and Compensation PlanOwnership Overview
14.82% Insiders
1.27% Mutual Funds
0.14% Other Institutional Investors
83.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.43 and its highest was $1.23 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $61.61M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Mar 12, 2025 which is in 53 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Nov 14, 2024. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.072 by $0.002.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Overvalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.06.
How many shares outstanding does VolitionRX have?
VolitionRX has 95,967,850 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.072. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
---
VolitionRX Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $254.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.24%
12-Months-Change
Fundamentals
Return on Equity
138.92%
Trailing 12-Months
Asset Growth
-29.71%
Trailing 12-Months
Company Description
VolitionRX
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Austin, TX.
---
VNRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with strong growth in sales and revenue, successful market expansion, and significant cost reductions. However, there are concerns about revenue predictability due to distributor stocking patterns, and the feline cancer test milestone remains pending.Read More>---
VNRX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
T2 Biosystems
―
OncoCyte
―
BioNano Genomics
―
Helius Medical Technologies
―
Karyopharm Therapeutics
―
Veracyte
―
Best Analysts Covering VNRX
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-32.74%
reiterated a buy rating 8 months ago
Copying Ross Osborn's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -32.74% per trade.
---